Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis.

Braden KuoCecilia ScimiaGeorge DukesWenwen ZhangSaurabh GuptaChunlin ChenEmil ChuangMichael Camilleri

Published in: Alimentary pharmacology & therapeutics (2021)

Trazpiroben was well tolerated with a favourable safety profile, supporting its further development for the treatment of gastroparesis. ClinicalTrials.gov identifier: NCT03268941.

Keyphrases

clinical trial
open label
double blind
study protocol
phase ii
randomized controlled trial
placebo controlled
phase iii